Van Eck Associates Corp Catalent, Inc. Transaction History

Van Eck Associates Corp

$80.1 Billion
Q3 2024

A detailed history of Van Eck Associates Corp transactions in Catalent, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 124,424 shares of CTLT stock, worth $7.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

124,424

Previous 84,441 47.35%

Holding current value

$7.56 Million

Previous $4.75 Million 55.67%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$56.16 - $60.96 $2.25 Million - $2.44 Million	39,983 Added 47.35%	124,424 $7.39 Million
Q2 2024 Jul 31, 2024	SELL	$53.58 - $57.02 $384,650 - $409,346	-7,179 Reduced 7.84%	84,441 $4.75 Million
Q1 2024 Apr 30, 2024	SELL	$42.56 - $59.82 $1.6 Million - $2.25 Million	-37,678 Reduced 29.14%	91,620 $5.17 Million
Q4 2023 Feb 05, 2024	SELL	$32.18 - $46.57 $1.46 Million - $2.11 Million	-45,401 Reduced 25.99%	129,298 $5.81 Million
Q3 2023 Nov 08, 2023	SELL	$44.2 - $50.2 $2.34 Million - $2.66 Million	-53,007 Reduced 23.28%	174,699 $7.95 Million
Q2 2023 Aug 03, 2023	BUY	$31.86 - $67.26 $2.38 Million - $5.02 Million	74,671 Added 48.79%	227,706 $9.87 Million
Q1 2023 May 03, 2023	SELL	$45.44 - $74.26 $5.05 Million - $8.25 Million	-111,068 Reduced 42.05%	153,035 $10.1 Million
Q4 2022 Feb 08, 2023	BUY	$41.39 - $81.0 $2.36 Million - $4.62 Million	57,088 Added 27.58%	264,103 $11.9 Million
Q3 2022 Oct 27, 2022	SELL	$72.36 - $113.1 $2.64 Million - $4.12 Million	-36,430 Reduced 14.96%	207,015 $15 Million
Q2 2022 Aug 03, 2022	BUY	$87.2 - $114.05 $6.99 Million - $9.14 Million	80,141 Added 49.07%	243,445 $26.1 Million
Q1 2022 May 10, 2022	BUY	$94.19 - $124.49 $3.6 Million - $4.76 Million	38,263 Added 30.6%	163,304 $18.1 Million
Q4 2021 Jan 26, 2022	BUY	$119.57 - $139.07 $2.39 Million - $2.78 Million	19,967 Added 19.0%	125,041 $16 Million
Q3 2021 Nov 03, 2021	BUY	$109.17 - $142.35 $1.18 Million - $1.54 Million	10,819 Added 11.48%	105,074 $14 Million
Q2 2021 Aug 10, 2021	SELL	$100.34 - $115.69 $61,107 - $70,455	-609 Reduced 0.64%	94,255 $10.2 Million
Q1 2021 May 13, 2021	SELL	$101.51 - $125.27 $3.46 Million - $4.27 Million	-34,114 Reduced 26.45%	94,864 $9.99 Million
Q4 2020 Feb 09, 2021	BUY	$85.88 - $105.36 $132,341 - $162,359	1,541 Added 1.21%	128,978 $13.4 Million
Q3 2020 Nov 12, 2020	BUY	$72.74 - $92.5 $755,550 - $960,797	10,387 Added 8.87%	127,437 $10.9 Million
Q2 2020 Aug 10, 2020	BUY	$48.02 - $79.04 $815,955 - $1.34 Million	16,992 Added 16.98%	117,050 $8.58 Million
Q1 2020 May 12, 2020	BUY	$36.95 - $62.95 $1.16 Million - $1.97 Million	31,272 Added 45.46%	100,058 $5.2 Million
Q4 2019 Feb 13, 2020	BUY	$47.06 - $56.64 $771,313 - $928,329	16,390 Added 31.28%	68,786 $3.87 Million
Q3 2019 Nov 08, 2019	SELL	$47.45 - $58.05 $2.12 Million - $2.6 Million	-44,776 Reduced 46.08%	52,396 $2.5 Million
Q2 2019 Aug 07, 2019	SELL	$39.26 - $54.21 $946,401 - $1.31 Million	-24,106 Reduced 19.88%	97,172 $5.27 Million
Q1 2019 May 13, 2019	SELL	$29.84 - $43.92 $3.51 Million - $5.16 Million	-117,572 Reduced 49.22%	121,278 $4.92 Million
Q4 2018 Feb 12, 2019	BUY	$29.95 - $46.34 $1.18 Million - $1.82 Million	39,275 Added 19.68%	238,850 $7.45 Million
Q3 2018 Nov 13, 2018	BUY	$40.12 - $45.55 $20,300 - $23,048	506 Added 0.25%	199,575 $9.09 Million
Q2 2018 Aug 13, 2018	SELL	$38.72 - $42.52 $361,064 - $396,499	-9,325 Reduced 4.47%	199,069 $8.34 Million
Q1 2018 May 11, 2018	BUY	$39.4 - $47.39 $1.67 Million - $2.01 Million	42,418 Added 25.56%	208,394 $8.56 Million
Q4 2017 Feb 12, 2018	BUY	$37.27 - $43.02 $337,330 - $389,374	9,051 Added 5.77%	165,976 $6.82 Million
Q3 2017 Nov 09, 2017	BUY	$33.75 - $41.67 $5.3 Million - $6.54 Million	156,925	156,925 $6.26 Million

Others Institutions Holding CTLT

# of Institutions

514

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.9B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Catalent, Inc. Transaction History